March 2024
03.22.2024 Medicines Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options
February 2024
02.06.2024 Medicines Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer 02.02.2024 Medicines Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
January 2024
01.26.2024 Vaccines Pfizer Receives Positive CHMP Opinion for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate for Infants and Children
December 2023
12.21.2023 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Syringe; 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Syringe; and Atropine Sulfate Injection, USP Lifeshield® ABBOJECT® Syringe 12.21.2023 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter 12.15.2023 Medicines Pfizer Receives Positive CHMP Opinion for Ulcerative Colitis Treatment
November 2023
11.13.2023 Medicines Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
October 2023
10.25.2023 Vaccines Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices 10.13.2023 Medicines Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma 10.05.2023 Medicines FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™ 10.02.2023 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due To The Potential For Presence of Glass Particulate Matter